Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01959438

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma (SECAR)

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma. A Phase I and Phase II Study.

Sponsor: Cancer and Allergy Foundation

Conditions Malignant Tumor Treatment Resistant Disorders Tumor Progression

Interventions Sodium selenite Sodium selenite (Introselen)

Updated 6 times since 2017 Last updated: Oct 8, 2013 Started: Feb 28, 2007 Primary completion: Oct 31, 2016 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Malignant Tumor and Treatment Resistant Disorders and is currently ongoing. Cancer and Allergy Foundation leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jul 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Jul 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer and Allergy Foundation
Cancerfonden
Cancerföreningen i Stockholm
Karolinska University Hospital
Region Stockholm

Data source: Karolinska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden